Holen Sie sich die Stockscreener-App
2.51
3.46%
-0.09
Handel nachbörslich:
2.47
-0.04
-1.59%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt FBIO?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$2.60
Offen:
$2.55
24-Stunden-Volumen:
697.28K
Relative Volume:
0.73
Marktkapitalisierung:
$80.83M
Einnahmen:
$63.26M
Nettoeinkommen (Verlust:
$-32.92M
KGV:
-21.00
EPS:
-0.1195
Netto-Cashflow:
$-71.34M
1W Leistung:
-7.04%
1M Leistung:
-24.85%
6M Leistung:
-19.29%
1J Leistung:
+65.13%
1-Tages-Spanne:
$2.45
$2.60
1-Wochen-Bereich:
$2.41
$2.90
52-Wochen-Spanne:
$1.325
$4.53
Fortress Biotech Inc Stock (FBIO) Company Profile
Firmenname
Fortress Biotech Inc
Sektor
Branche
Telefon
781-652-4500
Adresse
1111 KANE CONCOURSE, BAY HARBOR ISLANDS, NY
Compare FBIO vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FBIO
Fortress Biotech Inc
|
2.51 | 83.73M | 63.26M | -32.92M | -71.34M | -0.1195 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Fortress Biotech Inc Stock (FBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-03-15 | Fortgesetzt | ROTH MKM | Buy |
| 2022-08-04 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2020-10-02 | Eingeleitet | The Benchmark Company | Buy |
| 2019-12-18 | Eingeleitet | B. Riley FBR | Buy |
| 2018-02-28 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-07-11 | Eingeleitet | Rodman & Renshaw | Buy |
| 2017-03-22 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-10-03 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Fortress Biotech Inc Aktie (FBIO) Neueste Nachrichten
FBIO Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Fortress Biotech Inc (FBIO) Stock Price, Trades & News - GuruFocus
FBIO PE Ratio & Valuation, Is FBIO Overvalued - Intellectia AI
Fortress Biotech Inc reports results for the quarter ended December 31Earnings Summary - TradingView
FBIO SEC FilingsFortress Biotech Inc 10-K, 10-Q, 8-K Forms - stocktitan.net
Fortress Biotech (FBIO) CFO adds 2,967 ESPP shares in exempt grant - stocktitan.net
Fortress Biotech (NASDAQ:FBIO) Issues Quarterly Earnings Results, Misses Estimates By $0.32 EPS - marketbeat.com
Fortress Biotech: Q4 Earnings Snapshot - marketscreener.com
Fortress Biotech 2025 10-K: Revenue $63.3M, GAAP net loss $(32.9)M - TradingView
Fortress Biotech (NASDAQ: FBIO) boosts cash with PRV sale, royalties - stocktitan.net
Fortress Biotech (NASDAQ: FBIO) turns 2025 profit with $205M PRV sale and new royalties - stocktitan.net
Fortress Biotech Inc expected to post earnings of 11 cents a shareEarnings Preview - TradingView
Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights - marketscreener.com
フォートレス・バイオテック、2025年度財務実績及び直近の企業ハイライトを報告 - Moomoo
Avenue Therapeutics Focuses on Neurologic Disease Therapies with ATX-04 and IV Tramadol as Key Product Candidates in 2026 - Minichart
Fortress Biotech Subsidiary Sells Rare Disease Priority Voucher for $205M - National Today
Fortress Biotech Gains Cash From Voucher Sale, Simplifies Capital - TipRanks
Fortress Biotech (NASDAQ: FBIO) targets $100M+ from Cyprium PRV sale - stocktitan.net
Cyprium Therapeutics sells rare disease priority review voucher for $205 million - StreetInsider
Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million - ChartMill
Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million - Bitget
Why (FBIOP) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Aug Spikes: How do insiders feel about Fortress Biotech IncFed Meeting & Expert Curated Trade Ideas - baoquankhu1.vn
Fortress Biotech (NASDAQ:FBIO) Lowered to Hold Rating by Wall Street Zen - marketbeat.com
Fortress Biotech Inc Stock: Business Model, Pipeline Progress, and Investor Considerations in Biotec - AD HOC NEWS
Fortress Biotech Inc Stock: Journey Medical's Strong 2025 Results Highlight Growth Potential in Derm - AD HOC NEWS
Portfolio Recap: How does Fortress Biotech Inc score in quality rankingsOptions Play & Safe Entry Point Alerts - baoquankhu1.vn
Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights - GlobeNewswire
Portfolio Shifts: Can Fortress Biotech Inc deliver alphaQuarterly Earnings Summary & Smart Money Movement Alerts - baoquankhu1.vn
Fortress Biotech (FBIO) Projected to Post Quarterly Earnings on Monday - marketbeat.com
Fortress Biotech to Receive $205M as Cyprium Agrees Sale of Rare Pediatric Disease Priority Review Voucher - MSN
Buyback Watch: How liquid is Fortress Biotech Inc stock2026 Recap & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Fortress Biotech (FBIO) CEO Lindsay Rosenwald reports 20.7% ownership in 13D/A - Stock Titan
Fortress Biotech (FBIO) Executive Vice Chairman granted 475,424 restricted shares - Stock Titan
FORTRESS BIOTECH INC 9.375% Cumulative Redeemable Preferred Stock Series A USD25.00 (FBIOP.US) will release its earnings report after the market closes on March 25. - 富途牛牛
Mustang Bio, Inc. 2025 Annual Report: Clinical-Stage Biopharmaceutical Pipeline, Risks, and Regulatory Overview - Minichart
Mustang Bio (NASDAQ: MBIO) details GBM pipeline, Orphan status and cash - Stock Titan
Fortress Biotech (NASDAQ:FBIO) Cut to "Hold" at Zacks Research - MarketBeat
Fortress Biotech (NASDAQ:FBIO) Shares Pass Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Understanding Momentum Shifts in (FBIOP) - Stock Traders Daily
Macro Review: How do insiders feel about Fortress Biotech IncMarket Movers & Verified Momentum Stock Alerts - baoquankhu1.vn
Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026 - GlobeNewswire
Quarterly Earnings: Should value investors consider Fortress Biotech Inc2026 Growth vs Value & Consistent Profit Trade Alerts - baoquankhu1.vn
Fortress Biotech Inc Stock (ISIN: US32015L1035) Faces Short Interest Pressure Amid Biotech Sector Vo - AD HOC NEWS
Fortress Biotech (NASDAQ:FBIO) Stock Price Passes Above Two Hundred Day Moving AverageWhat's Next? - marketbeat.com
Swing Trade: How do insiders feel about Fortress Biotech IncCEO Change & Daily Technical Forecast Reports - baoquankhu1.vn
Avoiding Lag: Real-Time Signals in (FBIOP) Movement - Stock Traders Daily
Aug Sectors: How do insiders feel about Fortress Biotech IncMarket Performance Recap & Technical Entry and Exit Tips - baoquankhu1.vn
Aug Opening: What are the risks of holding Fortress Biotech IncJuly 2025 PreEarnings & Risk Controlled Swing Alerts - baoquankhu1.vn
Why Is Fortress Biotech Stock Falling Today? - Stocktwits
FBIO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Finanzdaten der Fortress Biotech Inc-Aktie (FBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):